|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STXBP4 |
Gene summary for STXBP4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STXBP4 | Gene ID | 252983 |
| Gene name | syntaxin binding protein 4 | |
| Gene Alias | Synip | |
| Cytomap | 17q22 | |
| Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | Q6ZWJ1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 252983 | STXBP4 | HCC1_Meng | Human | Liver | HCC | 3.49e-41 | 5.53e-02 | 0.0246 |
| 252983 | STXBP4 | HCC1 | Human | Liver | HCC | 1.99e-09 | 7.59e-01 | 0.5336 |
| 252983 | STXBP4 | HCC2 | Human | Liver | HCC | 1.21e-06 | 2.86e+00 | 0.5341 |
| 252983 | STXBP4 | S027 | Human | Liver | HCC | 3.55e-02 | 4.02e-01 | 0.2446 |
| 252983 | STXBP4 | S028 | Human | Liver | HCC | 3.64e-14 | 6.29e-01 | 0.2503 |
| 252983 | STXBP4 | S029 | Human | Liver | HCC | 2.14e-14 | 6.10e-01 | 0.2581 |
| 252983 | STXBP4 | HTA12-15-2 | Human | Pancreas | PDAC | 2.12e-04 | 4.24e-01 | 0.2315 |
| 252983 | STXBP4 | HTA12-23-1 | Human | Pancreas | PDAC | 4.09e-09 | 8.39e-01 | 0.3405 |
| 252983 | STXBP4 | HTA12-25-1 | Human | Pancreas | PDAC | 1.69e-04 | 5.71e-01 | 0.313 |
| 252983 | STXBP4 | HTA12-26-1 | Human | Pancreas | PDAC | 1.41e-07 | 5.83e-01 | 0.3728 |
| 252983 | STXBP4 | HTA12-29-1 | Human | Pancreas | PDAC | 2.95e-36 | 8.33e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:005082122 | Liver | HCC | protein stabilization | 139/7958 | 191/18723 | 1.61e-17 | 1.71e-15 | 139 |
| GO:003286821 | Liver | HCC | response to insulin | 172/7958 | 264/18723 | 7.14e-14 | 4.23e-12 | 172 |
| GO:003286921 | Liver | HCC | cellular response to insulin stimulus | 137/7958 | 203/18723 | 4.69e-13 | 2.44e-11 | 137 |
| GO:004343422 | Liver | HCC | response to peptide hormone | 247/7958 | 414/18723 | 9.55e-13 | 4.77e-11 | 247 |
| GO:007137521 | Liver | HCC | cellular response to peptide hormone stimulus | 179/7958 | 290/18723 | 2.54e-11 | 9.88e-10 | 179 |
| GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
| GO:00082862 | Liver | HCC | insulin receptor signaling pathway | 78/7958 | 116/18723 | 6.15e-08 | 1.29e-06 | 78 |
| GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
| GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
| GO:19019871 | Liver | HCC | regulation of cell cycle phase transition | 211/7958 | 390/18723 | 2.11e-06 | 2.89e-05 | 211 |
| GO:000974622 | Liver | HCC | response to hexose | 126/7958 | 219/18723 | 4.81e-06 | 6.06e-05 | 126 |
| GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
| GO:000974912 | Liver | HCC | response to glucose | 121/7958 | 212/18723 | 1.24e-05 | 1.39e-04 | 121 |
| GO:00448432 | Liver | HCC | cell cycle G1/S phase transition | 134/7958 | 241/18723 | 2.60e-05 | 2.70e-04 | 134 |
| GO:00343411 | Liver | HCC | response to interferon-gamma | 82/7958 | 141/18723 | 1.25e-04 | 1.03e-03 | 82 |
| GO:00713461 | Liver | HCC | cellular response to interferon-gamma | 70/7958 | 118/18723 | 1.66e-04 | 1.32e-03 | 70 |
| GO:004259322 | Liver | HCC | glucose homeostasis | 137/7958 | 258/18723 | 3.59e-04 | 2.49e-03 | 137 |
| GO:003350022 | Liver | HCC | carbohydrate homeostasis | 137/7958 | 259/18723 | 4.45e-04 | 2.98e-03 | 137 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STXBP4 | SNV | Missense_Mutation | c.782N>T | p.Arg261Ile | p.R261I | Q6ZWJ1 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STXBP4 | SNV | Missense_Mutation | novel | c.1645C>T | p.Pro549Ser | p.P549S | Q6ZWJ1 | protein_coding | tolerated_low_confidence(0.12) | benign(0.007) | TCGA-AR-A24W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | SD |
| STXBP4 | SNV | Missense_Mutation | novel | c.1658N>T | p.Ser553Ile | p.S553I | Q6ZWJ1 | protein_coding | deleterious_low_confidence(0) | benign(0.011) | TCGA-BH-A0BF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| STXBP4 | SNV | Missense_Mutation | c.1363N>G | p.Arg455Gly | p.R455G | Q6ZWJ1 | protein_coding | tolerated(0.07) | benign(0.046) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| STXBP4 | insertion | Frame_Shift_Ins | novel | c.353_354insCTTGATTAAA | p.Ser119LeufsTer30 | p.S119Lfs*30 | Q6ZWJ1 | protein_coding | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD | ||
| STXBP4 | SNV | Missense_Mutation | novel | c.1587N>C | p.Met529Ile | p.M529I | Q6ZWJ1 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STXBP4 | SNV | Missense_Mutation | c.823N>A | p.Ala275Thr | p.A275T | Q6ZWJ1 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-EA-A44S-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| STXBP4 | SNV | Missense_Mutation | c.167N>C | p.Gly56Ala | p.G56A | Q6ZWJ1 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| STXBP4 | SNV | Missense_Mutation | c.1111G>A | p.Glu371Lys | p.E371K | Q6ZWJ1 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| STXBP4 | SNV | Missense_Mutation | c.1080G>C | p.Gln360His | p.Q360H | Q6ZWJ1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |